27/11/2024
🌟 Breakthrough Therapy in the Fight Against Melanoma – New Hope for Patients! 🌟
Doctors around the world are asking themselves: how best to start treating patients with a new drug – lifileucel (Amtagvi), developed by Iovance Biotherapeutics. This is an innovative, personalized cellular therapy aimed at advanced melanoma that has progressed after standard treatments. The therapy shows about 30% effectiveness, which could bring new hope to many patients. 🌿
🔬 How does it work? Lifileucel is a therapy using TIL cells (tumor-infiltrating lymphocytes), which are taken directly from the patient’s surgically removed tumor. These cells are multiplied in the lab and then reintroduced into the patient’s body to fight the cancer. This process takes about 34 days – the time needed to prepare the treatment for each patient. 🧬
🏥 Where is it available? Specialized centers like Roswell Park Comprehensive Cancer Center are already ready to offer lifileucel treatment. However, not all facilities have the necessary infrastructure, which is one of the biggest challenges in making this therapy more widely available.
🔬 Hope for the future: Scientists like Dr. Allison Betof Warner and Dr. Igor Puzanov are continuously working to improve TIL therapy, aiming to increase its effectiveness and reduce its toxicity. Research is focused on lowering the need for high doses of chemotherapy before treatment and on replacing IL-2 therapy with less toxic alternatives. Another possible advancement could be genetic engineering of cytokines to enhance therapy’s effectiveness.
📈 Clinical trials confirm effectiveness: In an international study involving 73 patients, 31.5% responded positively to lifileucel treatment, with signs of response appearing as early as 1.5 months. This is a huge step forward in treating advanced melanoma!
Lifileucel opens new doors in solid tumor therapies, but research to further improve its efficacy is ongoing. Let’s hope this innovation leads to even better outcomes and becomes more accessible to patients worldwide. 💪🌍